Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2521 to 2535 of 8314 results

  1. Nogapendekin alfa inbakicept with intravesical BCG for non-muscle-invasive bladder cancer with carcinoma in situ that is unresponsive to BCG [ID6582]

    In development Reference number: GID-TA11767 Expected publication date:  04 November 2026

    Technology appraisal guidance
    In development

  2. Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]

    In development Reference number: GID-TA10575 Expected publication date:  22 April 2026

    Technology appraisal guidance
    In development

  3. In-situ normothermic regional perfusion of the abdomen for donor livers following circulatory death: draft scope consultation

    We are listening to your views on this Interventional procedures guidance. Comments close 19 December 2025.

    Interventional procedures guidance
    In consultation

  4. Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver: draft scope consultation

    We are listening to your views on this Interventional procedures guidance. Comments close 19 December 2025.

    Interventional procedures guidance
    In consultation

  5. Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297

    In development Reference number: GID-TA10311 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. STG320 for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites [ID1278]

    Awaiting development Reference number: GID-TA10279 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis [ID6487]

    In development Reference number: GID-TA11628 Expected publication date:  11 March 2026

    Technology appraisal guidance
    In development

  8. Nerandomilast for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis ID6446

    In development Reference number: GID-TA11552 Expected publication date:  25 September 2026

    Technology appraisal guidance
    In development

  9. Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps ID6379

    In development Reference number: GID-TA11429 Expected publication date:  25 September 2026

    Technology appraisal guidance
    In development

  10. Olezarsen for treating familial chylomicronaemia syndrome [ID6585]

    In development Reference number: GID-TA11678 Expected publication date:  19 August 2026

    Technology appraisal guidance
    In development

  11. Surgical mesh for ventral hernias

    In development Reference number: GID-HTE10080 Expected publication date: TBC

    Health technology evaluations
    In development

  12. Head injury (QS74) update

    In development Reference number: GID-QS10189 Expected publication date:  07 January 2027

    Quality standard
    In development

  13. Subcutaneous olanzapine for treating schizophrenia [TSID12289]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  14. Menotrophin prefilled pen for treating anovulation or during controlled ovarian hyperstimulation [TSID12290]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  15. Cyclosporin eye drops for treating moderate to severe keratoconjunctivitis [TSID12293]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation